Cellectis S.A. (NASDAQ:CLLS) Short Interest Update

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a significant drop in short interest in January. As of January 15th, there was short interest totalling 165,200 shares, a drop of 18.8% from the December 31st total of 203,500 shares. Based on an average daily trading volume, of 139,000 shares, the short-interest ratio is presently 1.2 days.

Cellectis Trading Down 1.8 %

Shares of CLLS stock traded down $0.03 during trading hours on Wednesday, hitting $1.60. 206,743 shares of the company were exchanged, compared to its average volume of 221,844. The firm has a fifty day moving average of $1.73 and a 200 day moving average of $1.95. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 1 year low of $1.41 and a 1 year high of $3.38. The firm has a market cap of $88.93 million, a PE ratio of -1.23 and a beta of 3.06.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. During the same quarter in the previous year, the business posted ($0.31) EPS. Analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

A hedge fund recently bought a new stake in Cellectis stock. First Affirmative Financial Network bought a new stake in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 21,094 shares of the biotechnology company's stock, valued at approximately $45,000. Hedge funds and other institutional investors own 63.90% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on CLLS. Barclays lowered their price target on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a report on Tuesday, November 5th. StockNews.com assumed coverage on shares of Cellectis in a research note on Friday, January 24th. They issued a "buy" rating for the company.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.